Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jun;69(6):1094–1097. doi: 10.1038/bjc.1994.214

Late mortality and levamisole adjuvant therapy in colorectal cancer.

R T Chlebowski 1, L Lillington 1, J S Nystrom 1, J Sayre 1
PMCID: PMC1969447  PMID: 8198976

Abstract

Beginning in 1975, 78 patients with resected stage B and C colorectal carcinoma were randomly assigned (2:1) to receive either levamisole 2.5 mg kg-1 day-1 given for 2 days every week for 18 months or placebo therapy in the same schedule. Pretreatment characteristics (age, gender, disease site, CEA and stage) and the pattern of follow-up were similar in both groups. For the first 5 years following randomisation, relapse-free survival and overall survival were similar in the two treatment groups. Subsequently, excess late mortality was associated with levamisole group assignment. Consequently, overall survival was somewhat greater in the placebo group than in the levamisole group, 68% vs 38% (P < 0.08). For patients surviving 5 years from randomisation, subsequent survival favoured placebo over levamisole (100% vs 57%; P < 0.03). The absolute numbers of deaths were 27 in the levamisole group (19 definitely cancer related) and seven in the group placebo (five definitely cancer related). This long-term result seen with a more intensive adjuvant levamisole dose and schedule suggests: (1) other levamisole adjuvant trials in patients with colorectal cancer should be examined for long-term outcome; (2) future trials utilising the even higher levamisole dosage required for clinical immunomodulation should proceed cautiously.

Full text

PDF
1094

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthony H. M., Mearns A. J., Mason M. K., Scott D. G., Moghissi K., Deverall P. B., Rozycki Z. J., Watson D. A. Levamisole and surgery in bronchial carcinoma patients: increase in deaths from cardiorespiratory failure. Thorax. 1979 Feb;34(1):4–12. doi: 10.1136/thx.34.1.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arnaud J. P., Buyse M., Nordlinger B., Martin F., Pector J. C., Zeitoun P., Adloff A., Duez N. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br J Surg. 1989 Mar;76(3):284–289. doi: 10.1002/bjs.1800760322. [DOI] [PubMed] [Google Scholar]
  3. Bancewicz J., Calman K. C., Macpherson S. G., McArdle C. S., McVie J. G., Soukop M. Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication. J R Soc Med. 1980 Mar;73(3):197–199. doi: 10.1177/014107688007300308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chlebowski R. T., Nystrom S., Reynolds R., Weiner J. M., Bateman J. R. Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a Western Cancer Study Group Trial. Oncology. 1988;45(3):141–143. doi: 10.1159/000226550. [DOI] [PubMed] [Google Scholar]
  5. Hook C. C., Kimmel D. W., Kvols L. K., Scheithauer B. W., Forsyth P. A., Rubin J., Moertel C. G., Rodriguez M. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol. 1992 Mar;31(3):262–267. doi: 10.1002/ana.410310306. [DOI] [PubMed] [Google Scholar]
  6. Janik J., Kopp W. C., Smith J. W., 2nd, Longo D. L., Alvord W. G., Sharfman W. H., Fenton R. G., Sznol M., Steis R. G., Creekmore S. P. Dose-related immunologic effects of levamisole in patients with cancer. J Clin Oncol. 1993 Jan;11(1):125–135. doi: 10.1200/JCO.1993.11.1.125. [DOI] [PubMed] [Google Scholar]
  7. Laurie J. A., Moertel C. G., Fleming T. R., Wieand H. S., Leigh J. E., Rubin J., McCormack G. W., Gerstner J. B., Krook J. E., Malliard J. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989 Oct;7(10):1447–1456. doi: 10.1200/JCO.1989.7.10.1447. [DOI] [PubMed] [Google Scholar]
  8. Moertel C. G. Accomplishments in surgical adjuvant therapy for large bowel cancer. Cancer. 1992 Sep 1;70(5 Suppl):1364–1371. doi: 10.1002/1097-0142(19920901)70:3+<1364::aid-cncr2820701526>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  9. Moertel C. G., Fleming T. R., Macdonald J. S., Haller D. G., Laurie J. A., Goodman P. J., Ungerleider J. S., Emerson W. A., Tormey D. C., Glick J. H. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990 Feb 8;322(6):352–358. doi: 10.1056/NEJM199002083220602. [DOI] [PubMed] [Google Scholar]
  10. Qiu F. X., Pang Q. F., Liu J. C., Song Y. Y., Xu A. Y., Wan X. B., Yin P. P., Suo Y. Q., Wang F. L., Jiang H. Y. Further studies on the etiology of autumn infant gastroenteritis. Chin Med J (Engl) 1981 Feb;94(2):94–100. [PubMed] [Google Scholar]
  11. Sertoli M. R., Guarneri D., Rubagotti A., Porcile G., Nobile M. T., Rosso R. Adjuvant immunochemotherapy in colorectal cancer Dukes C. Oncology. 1987;44(2):78–81. doi: 10.1159/000226449. [DOI] [PubMed] [Google Scholar]
  12. Stevenson H. C., Green I., Hamilton J. M., Calabro B. A., Parkinson D. R. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol. 1991 Nov;9(11):2052–2066. doi: 10.1200/JCO.1991.9.11.2052. [DOI] [PubMed] [Google Scholar]
  13. Treurniet-Donker A. D., Meischke-de Jongh M. L., van Putten W. L. Levamisole as adjuvant immunotherapy in breast cancer. Cancer. 1987 May 1;59(9):1590–1593. doi: 10.1002/1097-0142(19870501)59:9<1590::aid-cncr2820590911>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  14. Windle R., Bell P. R., Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg. 1987 Jul;74(7):569–572. doi: 10.1002/bjs.1800740707. [DOI] [PubMed] [Google Scholar]
  15. Wolmark N., Rockette H., Fisher B., Wickerham D. L., Redmond C., Fisher E. R., Jones J., Mamounas E. P., Ore L., Petrelli N. J. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993 Oct;11(10):1879–1887. doi: 10.1200/JCO.1993.11.10.1879. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES